Hormonal
Obesity is an independent, chronic non-communicable disease that directly causes cardiovascular disease through pathophysiological mechanisms including insulin resistance, endothelial dysfunction, and inflammation, rather than merely amplifying other risk factors.
Stop viewing obesity as just a lifestyle choice or a minor risk factor. It is a chronic disease with specific biological mechanisms (like inflammation and hormonal imbalance) that directly damage your heart and blood vessels. This means you deserve and need medical treatment, not just willpower-based advice, to manage it effectively and prevent heart disease.
obesity has been considered for a long time a minor risk factor or even a simple amplifier of the recognized role of the other well established CV risk factors... Only in 2021 obesity has been finally acknowledged as a definite pathological identity and identified as a recurrent, chronic non-communicable disease.
Why this rating
The paper cites multiple large-scale epidemiological studies, meta-analyses, and consensus documents from the Italian Society of Cardiovascular Prevention.
Source
Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC)
Massimo Volpe et al. · Frontiers in Cardiovascular Medicine · 2023
DOI 10.3389/fcvm.2023.1136340
More from this paper
- GLP-1 receptor agonists (semaglutide 2.4 mg and liraglutide 3 mg) produce significant body weight reduction (up to 20% with semaglutide) and improve cardiovascular risk factors, with semaglutide showing superiority in weight loss compared to previous drugs.Strong
- Bariatric/metabolic surgery (BMS) is the most effective strategy for significant and sustained body weight reduction (14-25%) and reduces the risk of hypertension, diabetes, and mortality, but remains underused.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →